Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

NCT07411586 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Ziftomenib
DRUG: Olutasidenib

Sponsor

M.D. Anderson Cancer Center